GENE ONLINE|News &
Opinion
Blog

2021-08-02| SpecialTechnology

Realizing The Promise of Cell And Gene Therapies: Current Challenges And Future Opportunities

by Kathy Huang
Share To
The cell and gene therapy market is booming with several global companies advancing their latest innovations to Phase 2 and late-stage trials.

At the regulatory level, although only a handful of products have been approved hitherto, the FDA expects to review close to 10 to 20 cell and gene therapy IND applications each year by 2025. At this juncture, the industry is striving to strike a balance between a continuous flow of innovations and streamline existing candidates within the manufacturing, regulatory and policy climate of prevailing frameworks. In a BIO Asia-Taiwan session, experts from big pharma, regulatory affairs, and academia discussed the current developments in the field, besides its potential and challenges for the future.

GO Prime with only $1.49 now

LATEST
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
2021-12-02
EVENT
2021-12-13
63rd ASH ANNUAL MEETING AND EXPOSITION
Georgia, USA
2021-12-28
BIOHK2021
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!